Stay updated on Umbralisib Plus Pembrolizumab in Hodgkin Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Umbralisib Plus Pembrolizumab in Hodgkin Lymphoma Clinical Trial page.

Latest updates to the Umbralisib Plus Pembrolizumab in Hodgkin Lymphoma Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe page has undergone significant changes, including the removal of detailed descriptions of a Phase II trial for umbralisib and pembrolizumab in treating classical Hodgkin lymphoma, while adding new identifiers and collaborators related to the study.SummaryDifference42%
- Check17 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check24 days agoNo Change Detected
- Check60 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check75 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
- Check82 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.1%
- Check96 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.1%
Stay in the know with updates to Umbralisib Plus Pembrolizumab in Hodgkin Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Umbralisib Plus Pembrolizumab in Hodgkin Lymphoma Clinical Trial page.